ArticleCurrent oncology (Toronto, Ont.)2026
Assessing the Opportunity for an Accelerated Access Pathway for Health Canada Priority Review Drugs: A Comparative Analysis with Ontario's FAST Pilot Program.
Article in Current oncology (Toronto, Ont.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTimely public reimbursement of innovative medicines remains a challenge in Canada despite expedited regulatory review pathways. This study evaluated whether an accelerated reimbursement pathway, similar to Ontario's Funding Accelerated for Specific Treatments (FAST) for oncology drugs approved through Project Orbis could improve access for therapies approved through Health Canada's Priority Review (PR) pathway, extending to indications beyond oncology.
methodsHealth Canada drug submissions completed between 2021 and 2025 were reviewed to characterize PR, Notice of Compliance with conditions (NOC/c), and Project Orbis. Drug submissions completed in 2022 were selected for detailed analysis. Drug review and approval process data were compiled from Health Canada (HC), Canada's Drug Agency (CDA-AMC), the pan-Canadian Pharmaceutical Alliance (pCPA), Ontario government, and manufacturer sources. Time from Health Canada Notice of Compliance (NOC) to Ontario public listing was compared for Orbis, PR non-Orbis, and FAST therapies.
resultsAmong drugs approved in 2022, mean time from NOC to Ontario listing was 625.29 ± 365.80 days for PR non-Orbis and 604.18 ± 283.92 days for Orbis. FAST therapies were listed in 229.22 ± 140.50 days, approximately 60% faster than Orbis and PR non-Orbis. Half of PR approvals in 2022 were not associated with Project Orbis and were therefore ineligible for existing accelerated reimbursement pathways.
conclusionsThe Ontario FAST program is associated with substantially shorter times to public listing for novel oncology medicines. Extending a similar accelerated access pathway to therapies approved through PR could improve timely and equitable patient access in Canada.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.